| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 544366000 | Five-membered hetero ring having two or more ring hetero atoms of which at least one is nitrogen | 47 |
| 20120101277 | CRYSTALLINE FORM OF POSACONAZOLE - The present invention relates to crystalline form II-S, its preparation and its use to prepare other crystalline forms of posaconazole, in particular crystalline form IV of posaconazole. | 04-26-2012 |
| 20130203993 | PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES - The present invention relates to a process for the preparation of a chiral compound according to formula (V) wherein R | 08-08-2013 |
| 20130203994 | PREPARATION OF POSACONAZOLE INTERMEDIATES - The present invention relates to process for the preparation of a chiral compound of formula (IX) or a salt thereof, wherein Y | 08-08-2013 |
| 20130211086 | PURIFICATION OF POSACONAZOLE AND OF POSACONAZOLE INTERMEDIATES - The present invention relates to a process for the preparation of a hydrogen chloride (HCl) salt of a compound of formula (I) wherein Y | 08-15-2013 |
| 20140343285 | Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof - A process for the preparation of 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one compound of formula-1, its intermediates and polymorphs thereof. (I) | 11-20-2014 |
| 544367000 | Ring chalcogen in the five-membered hetero ring | 30 |
| 20090023924 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES - Processes and intermediates for the preparation of compounds of the Formula (1) and the pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, wherein R | 01-22-2009 |
| 20130203995 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 - Processes for making 7-methyl-5-(3piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one | 08-08-2013 |
| 544368000 | The five-membered hetero ring is one of the cyclos in a polycyclo ring system | 15 |
| 20080214816 | Process for Preparing Ziprasidone - Process for preparing ziprasidone. The present invention concerns a process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one of the formula I, or a pharmaceutically acceptable acid addition salt, solvate, hydrates or clathrate thereof, said process comprising reacting a compound of formula II wherein X is a halogen atom, with a compound of formula III, said compound of formula III being the free base or an addition salt with an organic or inorganic acid, wherein said process is characterized in that said compounds according to formulas II and III are reacted in the presence of a neutralizing agent, and are reacted in a solvent comprising acetonitrile. | 09-04-2008 |
| 20090030204 | Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same - The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof. | 01-29-2009 |
| 20090111988 | NOVEL PROCESS FOR PRODUCTION OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE (ZIPRASIDONE) - The present invention provides a novel, industrially easily realisable and economically preferable process for production of pure 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one i.e., ziprasidone hydrochloride shown in the reaction scheme (II), (III), (IV), (V) and (VI). According to the invention the intermediate compound 5-(2-bromoethyl)-6-chloro-1,3-dihydro-2H-indol-2-one of Formula (III) is produced from 5-(2-bromoacethyl)-6-chloro-1,3-dihydro-2H-indole-2-one of Formula (IV). The highly pure ziprasidone base of Formula (II) is obtained in the reaction of 3-piperazinyl-1,2-benzisothiazol of Formula (VI) with 5-(2-bromoethyl)-6-chloro-1,3-dihydro-2H-indol-2-one of Formula (III) in an organic solvent or organic solvent mixture. | 04-30-2009 |
| 20090312550 | ZIPRASIDONE FREE FROM COLORED IMPURITIES AND A PROCESS FOR ITS PREPARATION - Ziprasidone base or a pharmaceutically acceptable salt thereof free from colored impurities, in particular those giving the product a “slightly pink to pink” coloration. | 12-17-2009 |
| 20110003994 | CYCLOALKANE DERIVATIVE - The present invention relates to a novel cycloalkane derivative which exhibits an excellent psychotropic action and has less side effect. | 01-06-2011 |
| 20110003995 | Process for the Preparation of Ziprasidone - The present invention relates to a process for preparing Ziprasidone of formula I, | 01-06-2011 |
| 20110207933 | PROCESS FOR THE PREPARATION OF ZIPRASIDONE - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 08-25-2011 |
| 20120016124 | SEROTONIN REUPTAKE INHIBITORS - A serotonin reuptake inhibitor which can be used in the treatment of depression and which has a decreased occurrence of unwanted side effects. The serotonin reuptake inhibitors are bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT | 01-19-2012 |
| 20120095231 | UREA DERIVATIVE - Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity.
| 04-19-2012 |
| 20130289277 | MEDICAMENT FOR TREATING MENTAL AND BEHAVIOURAL DISORDERS - The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof. | 10-31-2013 |
| 20140031548 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 01-30-2014 |
| 20140039190 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF - Compounds of general formula A useful as potential anticancer agents against human cancer cell lines and a process for the preparation thereof. | 02-06-2014 |
| 20140179922 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF - The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes. | 06-26-2014 |
| 20140243529 | PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE - Disclosed is a new and efficient process for the synthesis with high yields and purity of lurasidone hydrochloride, a medicament which is useful as a psychotropic substance. The process involves the preparation of lurasidone base in a reaction system not containing inorganic salts, followed by conversion of the latter to an addition salt with an organic carboxylic acid, which is finally converted to lurasidone hydrochloride. | 08-28-2014 |
| 20160176830 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | 06-23-2016 |
| 544369000 | 1,3-oxazole ring or 1,3-thiazole ring (including hydrogenated) | 13 |
| 20090203908 | Activator for Peroxisome Proliferator-Activated Receptor - A compound having the following formula or its salt is used as an activator for PPAR: | 08-13-2009 |
| 20090216016 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF - The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H -pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine (compound I) useful as a dipeptidyl peptidase-IV inhibitor, which has superior properties of stability and hygroscopicity, and reproducible crystal structure, and a production method thereof. | 08-27-2009 |
| 20100022772 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES - The present invention relates to processes for the preparation of biaryl oxazolidinones. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. | 01-28-2010 |
| 20100069638 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY - The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. | 03-18-2010 |
| 20100145048 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 06-10-2010 |
| 20110282058 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF - The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin- | 11-17-2011 |
| 20130066076 | Process for the Synthesis of Biaryl Oxazolidinones - The present invention relates to processes for the preparation of biaryl oxazolidinones. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. | 03-14-2013 |
| 20130085279 | CRYSTALLINE HYDROCHLORIDE SALT OF (1-(4-FLUOROPHENYL)-1H-INDOL-5-YL)-(3-(4-(THIAZOLE-2-CARBONYL)PIPERAZIN-1- -YL)AZETIDIN-1-YL)METHANONE - The present invention relates to a crystalline hydrochloride salt of (1-(4-fluorophenyl)-1H-indol-5-yl)(3-(4-(thiazole-2-carbonyl)piperazin-1-yl)azetidin-1-yl)methanone, methods of making said salt, pharmaceutical compositions containing said salt, and the use of said salt in the treatment of pain and diseases that cause such pain, and metabolic disorders such as, obesity, hyperphagia, and diabetes. | 04-04-2013 |
| 20130102783 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS - Compounds of formula (1) | 04-25-2013 |
| 20140058105 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS - Compounds of formula (1) | 02-27-2014 |
| 20140221654 | PROTEASE INHIBITORS - Compounds of the formula II: | 08-07-2014 |
| 20140364610 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES - The present invention relates to certain heteroaromatic compounds of Formula (Ia), or pharmaceutically acceptable salts thereof, and uses of such compounds in the treatment of synucleopathies. | 12-11-2014 |
| 20160068539 | PROTEASE INHIBITORS - Compounds of the formula II: | 03-10-2016 |
| 544370000 | 1,3-diazole ring (including hydrogenated) | 8 |
| 20090118510 | Dark coloured azo dyes - The present invention relates to
| 05-07-2009 |
| 20090275753 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG - A compound represented by formula (1) or a salt thereof, and an antioxidant drug containing the compound or the salt as an active ingredient, are provided. The compound or salt exhibits effective antioxidant activity in treating ischemic organ disorders and diseases caused by oxidative cell damage, and in inhibiting retinal lesions caused by oxidation due to the effects of light. | 11-05-2009 |
| 20100105907 | CONTINUOUS ANTISOLVENT CRYSTALLIZATION PROCESS AND SYSTEM USING PLUG FLOW REACTORS - A process and system for continuous crystallization of a compound using antisolvent addition in which a solution is prepared with an organic compound and a solvent. An antisolvent is added to the solution in a continuous plug flow system comprising at least one process module. The antisolvent can be added in multiple addition points such that the overall amount of antisolvent added to the continuous plug flow reactor remains fixed. The multiple addition point technique provides every process module with an equal volume of antisolvent. Finally, crystals are recovered from the slurry upon exiting the system. Preferably, the mean crystal size is less than 100 μm. | 04-29-2010 |
| 20100222588 | Method for Manufacture of 2-Oxoimidazolidines - There is provided a method for manufacture of 2-oxoimidazolidines of Formula I comprising one or more of the steps of converting an amine to an acylation agent, condensation of the acylation agent with a bi-functional compound of structure L-C(R | 09-02-2010 |
| 20130225817 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES - A method for the manufacture of 2-oxoimidazolidines comprising the steps of converting an isocyanate and an amine to a urea, and then performing a ring closure of the urea to yield the 2-oxoimidazolidine is disclosed. The 2-oxoimidazolidines produced may then be used in the production of Pramiconazole and other structurally related compounds. | 08-29-2013 |
| 20130237705 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES - A method for the manufacture of 2-oxoimidazolidines comprising the steps of converting an isocyanate and an amine to a urea, and then performing a ring closure of the urea to yield the 2-oxoimidazolidine is disclosed. The 2-oxoimidazolidines produced may then be used in the production of Pramiconazole and other structurally related compounds. | 09-12-2013 |
| 20140343286 | ANTI-VIRAL COMPOUNDS - The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. | 11-20-2014 |
| 20150031884 | ANTI-VIRAL COMPOUNDS - The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. | 01-29-2015 |
| 544371000 | 1,2-diazole ring (including hydrogenated) | 4 |
| 20090023925 | N'-(2-HALOBENZYLIDENE)SULFONYLHYDRAZIDES AS INTERMEDIATES IN THE MANUFACTURE OF ARYLSULFONYLINDAZOLES - The present invention provides N′-(2-halobenzylidene)sulfonylhydrazides of formula I | 01-22-2009 |
| 20090198060 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR - Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. | 08-06-2009 |
| 20100063286 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder. | 03-11-2010 |
| 20100094006 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF - The present invention relates to pyrazolylmethylamine-piperazine derivatives and their pharmaceutically acceptable salts effective as calcium channel modulators and a method of manufacturing the same. The present invention also relates to the medicinal use of the above compounds as therapeutic treatment of diseases due to their effect as calcium channel modulators. | 04-15-2010 |
